Targets › FXI
1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Mar 2028.
Open in Phaseline: the race on FXI, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| City Therapeutics | CITY-FXI siRNA targeting Factor XI | FXI | Phase 1 | Factor V Leiden | Mar 2028 |
Factor V Leiden (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.